Calgary, Alberta – April 30, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share part of the second final data set from its preclinical Rett...
Calgary, Alberta – April 16, 2025 – Marvel Biosciences Corp. (TSXV: MRVL, OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together “Marvel”), are pleased to announce their acceptance to give an oral presentation at the International Rett...
Calgary, Alberta – April 14, 2025 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), is pleased to announce that it has been invited to present its latest research...
Calgary, Alberta, Canada, March 28, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that, subject to approval of the TSX Venture Exchange...
Calgary, Alberta – March 17, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and...
Calgary, Alberta – March 13, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share part of the final data from its preclinical Rett syndrome...
